Skip to main content
. Author manuscript; available in PMC: 2019 Nov 14.
Published in final edited form as: Cell Host Microbe. 2018 Nov 14;24(5):731–742.e6. doi: 10.1016/j.chom.2018.10.008

Figure 1:

Figure 1:

Cross-reactive DENV monoclonal antibodies (mAbs) enhance ZIKV infection of human placental macrophages (HCs). A) Binding and neutralization properties of mAbs. B) HCs were infected with ZIKV (MOI 1) in the presence of DENV cross-reactive mAbs or EM4CO4 non-specific control (five-fold dilutions starting at 10 µg/mL). Intracellular ZIKV E protein was assessed by 4G2 staining at 24 hours post-infection (hpi). Antibody dilutions were performed in singlicate. Control conditions are shown as the average of biological triplicates ±SD. Representative experiment from n=2 donors. Ab−, no mAb. ZIKV−, no ZIKV. C) HCs were infected with ZIKV (MOI 1) in the presence of mAb 33.3A06 (five-fold dilutions starting at 0.4 ug/ml) or EM4CO4 (0.4 ug/ml). Intracellular ZIKV E protein was assessed by 4G2 staining at 24 hpi (biological triplicates ±SD). Representative experiment from n=3 donors. D) Infectious virus in the supernatant was assessed by focus-forming assay (FFA) at 24 hpi (biological triplicates ±SD). Representative experiment from n=3 donors. FFU, focus-forming units. E) Representative FFA.